For decades, translational medicine has faced a frustrating bottleneck: why do over 90% of oncology and neurology drug candidates that show dazzling success in preclinical lab testing ultimately fail when injected into human patients? The answer lies in the structural limitations of our screening models. Traditional 2D cell monolayers flat-line the natural three-dimensional spatial architecture...
Date: August 11, 2026
Time: 11:00 AM – 12:00 PM EDT
Featured Guest Speaker: Dr. Ivelin Georgiev
Monoclonal antibodies stand out as highly powerful preventive and therapeutic modalities against complex infectious diseases, diverse cancers, and autoimmune conditions. However, conventional antibody discovery workflows continue to hit a wall. Biopharma teams routinely...
0 Commentarios
0 Acciones
191 Views
0 Vista previa
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek